Study to Evaluate the Performance and Safety of Expedial and Compare it to Expanded Polytetrafluoroethylene (ePTFE) Vascular Access Grafts
End Stage Renal Disease
About this trial
This is an interventional treatment trial for End Stage Renal Disease focused on measuring vascular access graft, hemodialysis, dialysis, end stage renal disease
Eligibility Criteria
Inclusion Criteria: Patient has chronic renal failure and requires vascular access for hemodialysis Patient has given informed consent to participate in the trial and is willing to comply with the study protocol Patient is male or female, 18 years of age or older The vascular access graft can be placed in the upper extremity (forearm, including across the elbow, or upper arm) Patient is undergoing or will undergo hemodialysis at a hospital or hemodialysis center Patient has a vein 4 mm or larger to which the graft can be anastomosed Exclusion Criteria: Patient is unable to comply with the study follow-up Patient has a known sensitivity to polyurethane or porcine heparin Patient has a previous vascular access graft implanted and it is not possible to place the study graft proximal to the existing device and no other sites are available Patient has an immunodeficiency syndrome Patient has a prior history of bacterial infection within 8 weeks of implantation of graft Patient has a severe coagulation disorder Patient has an elevated platelet count of greater than 1 million Patient has a history of heparin-induced thrombocytopenia syndrome (HIT) Patient is pregnant Patient has a fever greater than 100 degrees Fahrenheit
Sites / Locations
- Vascular and General Surgery
- Vascular Surgery Associates
- Montefiore Medical Center
- Vascular Surgery
- Duke University Medical Center
- General Surgery
- South Carolina Associates for Cardiac and Vascular Disease; Greenville Hospital System
- Peripheral Vascular Associates